News Headlines Article

Heart transplant test maker to gov’t agency: You’re killing us
San Francisco Business Times

Unless the federal agency that sets reimbursement rates for Medicare has a change of heart, a Peninsula company with a test that helps predict heart transplant rejection could have three months to live. That’s no exaggeration, says Peter Maag, the president and CEO of CareDx Inc. (NASDAQ: CDNA): A proposed 77 percent drop in the rate that Medicare would reimburse the Brisbane company for its AlloMap test is less than CareDx’s costs.